Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci; Ruud Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; E Schimmel; S Krol; PP van der Toorn; H de Jager; W Heemsbergen; Ben Heijmen; F Pos

doi:10.1016/s1470-2045(16)30070

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Luca Incrocci, Ruud Wortel, Wendimagegn Ghidey Alemayehu, Shafak Aluwini, E Schimmel, S Krol, PP van der Toorn, H de Jager, W Heemsbergen, Ben Heijmen, F Pos

Radiation Oncology

Research output: Contribution to journal › Article › Academic › peer-review

313 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1061-1069
Number of pages	9
Journal	Lancet Oncology
Volume	17
Issue number	8
DOIs	https://doi.org/10.1016/s1470-2045(16)30070
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/s1470-2045(16)30070

Cite this

Incrocci, L., Wortel, R., Ghidey Alemayehu, W., Aluwini, S., Schimmel, E., Krol, S., van der Toorn, PP., de Jager, H., Heemsbergen, W., Heijmen, B., & Pos, F. (2016). Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, 17(8), 1061-1069. https://doi.org/10.1016/s1470-2045(16)30070

@article{9a7f1186f57d4dec8c7b6119d60bfc76,

title = "Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial",

author = "Luca Incrocci and Ruud Wortel and {Ghidey Alemayehu}, Wendimagegn and Shafak Aluwini and E Schimmel and S Krol and {van der Toorn}, PP and {de Jager}, H and W Heemsbergen and Ben Heijmen and F Pos",

year = "2016",

doi = "10.1016/s1470-2045(16)30070",

language = "Undefined/Unknown",

volume = "17",

pages = "1061--1069",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

Incrocci, L, Wortel, R, Ghidey Alemayehu, W, Aluwini, S, Schimmel, E, Krol, S, van der Toorn, PP, de Jager, H, Heemsbergen, W, Heijmen, B & Pos, F 2016, 'Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial', Lancet Oncology, vol. 17, no. 8, pp. 1061-1069. https://doi.org/10.1016/s1470-2045(16)30070

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. / Incrocci, Luca; Wortel, Ruud; Ghidey Alemayehu, Wendimagegn et al.

In: Lancet Oncology, Vol. 17, No. 8, 2016, p. 1061-1069.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

AU - Incrocci, Luca

AU - Wortel, Ruud

AU - Ghidey Alemayehu, Wendimagegn

AU - Aluwini, Shafak

AU - Schimmel, E

AU - Krol, S

AU - van der Toorn, PP

AU - de Jager, H

AU - Heemsbergen, W

AU - Heijmen, Ben

AU - Pos, F

PY - 2016

Y1 - 2016

U2 - 10.1016/s1470-2045(16)30070

DO - 10.1016/s1470-2045(16)30070

M3 - Article

VL - 17

SP - 1061

EP - 1069

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -